Design, synthesis, and anticonvulsant activity of 1-(pyrid-3- ylsulfonamido)-2-nitroethylenes

Journal of Medicinal Chemistry

Volumn 41, Issue 17, 1998, Pages 3239-3244

  Masereel, Bernard ^a   Wouters, Johan ^a   Pochet, Lionel ^a   Lambert, Didier ^b  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 (PYRID 3 YLSULFONAMIDO) 2 NITROETHYLENE DERIVATIVE; AMPHOLYTE; ANTICONVULSIVE AGENT; BICUCULLINE; BM 34; BM 401; N METHYL DEXTRO ASPARTIC ACID; PENTETRAZOLE; PHENYTOIN; PICROTOXIN; STRYCHNINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIURESIS; DRUG CONFORMATION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; LIPOPHILICITY; MALE; MOLECULAR MODEL; MOUSE; NEUROTOXICITY; NONHUMAN; RAT; SEIZURE; TONIC CLONIC SEIZURE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTICONVULSANTS; CONVULSANTS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ELECTROSHOCK; MALE; MICE; MICE, INBRED STRAINS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NEUROTOXINS; PHENYTOIN; SEIZURES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOUREA;

EID: 0032514471     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981022n     Document Type: Article

References (26)

1. Thornber, C. W. Isosterism and molecular modification in drug design. Chem. Soc. Rev. 1979, 8, 563-580.
2. Ganellin, C. R. Discovery of cimetidine. In The role of organic chemistry in drug research; Roberts, S. M., Price, B. S., Eds.; Academic Press: London, 1985; pp 93-118.
3. Brogden, R. N.; Carmine, A. A.; Heel, R. C.; Speight, T. M.; Avery, G. S. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1982, 24, 267-303.
4. Lambert, D. M.; Masereel, B.; Gallez, B.; Geurts, M.; Scriba, G. K. E. Bioavailability and anticonvulsant activity of 2-cyanoguanidinophenytoin, a structural analogue of phenytoin. J. Pharm. Sci. 1996, 85, 1077-1081.
5. Masereel, B.; Laeckmann, D.; Dupont, L.; Liégeois, J. F.; Pirotte, B.; de Tullio, P.; Delarge, J. Synthesis and pharmacology of pyrid-3-yl sulfonylcyanoguanidines as diuretics. Eur. J. Med. Chem. 1995, 30, 343-351.
6. Masereel, B.; Lebrun, P.; Dogné, J. M.; de Tullio, P.; Pirotte, B.; Pochet, L.; Diouf, O.; Delarge, J. First synthesis of sulfonylcyanoguanidines. Tetrahedron Lett. 1996, 37, 7253-7254.
7. Masereel, B.; Ouedraogo, R.; Dogné, J. M.; Antoine, M. H.; de Tullio P.; Pirotte, B.; Pochet, L.; Delarge, J.; Lebrun, P. Sulfonylcyanoguanidines and sulfonamido nitroethylenes as bioisosteres of hypoglycemic sulfonylureas. Eur. J. Med. Chem. 1997, 32, 453-456.
8. Friedel, H. A.; Buckley, M. M. T. Torasemide. A review of its pharmacological and therapeutic potential. Drugs 1991, 41, 81-103.
9. Masereel, B.; Lambert, D. M.; Dogné, J. M.; Poupaert, J. H.; Delarge, J. Anticonvulsant activity of pyrid-3-yl sulfonyl urea and thiourea. Epilepsia 1997, 38, 334-337.
10. Faingold, C. L. Neuronal networks, epilepsy, and the action of antiepileptic drugs. In Drugs for control of epilepsy: actions of neuronal networks involved in seizure disorders; Faingold, C. L., Fromm, G. H., Eds.; CRC Press: Boca Raton, FL, 1992; pp 1-21.
11. Macdonald, R. L.; Kelly, K. M. Antiepileptic drug mechanisms of action. Epilepsia 1995, 36, S2-S12.
12. Meldrum, B. S. Update on the mechanism of action of anti-epileptic drugs. Epilepsia 1996, 37, S4-S11.
13. Gompper, R.; Schaefer, H. Beiträge zur chemie der dithiocarbonsäureester und ketenmercaptale. Chem. Ber. 1967, 100, 591-604.
14. White, G. R. Procédé perfectionné pour la préparation de dérivés d'éthylène et produits obtenus par ce procédé. Belg. Pat. 841,526 1976.
15. +. In vitro study. J. Pharm. Pharmacol. 1992, 44, 589-593.
16. + co-transporter. Eur. J. Med. Chem. 1994, 29, 527-537.
17. Hacksell, U. Structural and Physiological Factors in Drug Action. In A Textbook of Drug Design and Development, 2nd ed.; Krogsgaard-Larsen, P., Liljefors, T., Madsen, U., Eds.; Harwood Academic Publishers: Amsterdam, 1996; pp 35-59.
18. Bechalany, A.; Röthlisberger, T.; El Tayar, N.; Testa, B. Comparison of Various Non-Polar Stationary Phases Used for Assessing Lipophilicity. J. Chromatogr. 1989, 473, 115-124.
19. Porter, R. J.; Cereghino, J. J.; Gladding, G. D.; Hessie, B. J.; Kupferberg, H. J.; Scoville, B.; White, B. G. Antiepileptic drug development porgram. Cleve. Clin. Q. 1984, 51, 293-305.
20. Dunham, N. W.; Miya, T. A. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. 1957, 46, 208-209.
21. 3). Acta Crystallogr. 1978, B34, 1304-1310.
22. Retsagi, G.; Kelly, J. P.; Kaufman, D. W. Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. Brit. Med. J. 1988, 297, 262-265.
23. Arneborn, P.; Palmblad, J. Drug induced neutropenia. A survey for Stockholm 1973-1978. Acta Med. Scand. 1982, 212, 289-292.
24. Cloux, J. L.; Crommen, J.; Delarge, J.; Pirard, M. L.; Thunus, L. Tentative de détermination de la constante fragmentaire (f) du groupement sulfonylurée. J. Pharm. Belg. 1988, 43, 141-151.
25. Litchfield, J. T.; Wilcoxon, F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949, 96, 99-102.
26. Czuczwar, S. J.; Frey, H. H.; Löscher, W. Antagonism of N-methyl-D,L-aspartic acid-induced convulsions by antiepileptic drugs and other agents. Eur. J. Pharmacol. 1984, 108, 273-280.